Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Mar 24, 2026; 17(3): 116062
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.116062
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.116062
Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease
Aisha Jamil, Department of Obstetrics and Gynaecology, Type C Hospital Karak, Karak 27200, Khyber Pakhtunkhwa, Pakistan
Ghulam Sughra, Department of Obstetrics and Gynaecology, Asian Institute of Medical Sciences, Hyderabad 71000, Sindh, Pakistan
Ghazala Dawood Abbasi, Department of Obstetrics and Gynaecology, Islamic International Medical College, Sargodha 40100, Punjab, Pakistan
Soukaina Adane, Department of Obstetrics and Gynaecology, Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China
Monica Punshi, Department of Obstetrics and Gynaecology, Dr. Ruth KM Pfau Civil Hospital, Karachi 74400, Sindh, Pakistan
Mobashara Ghulam Muhammad, Department of Obstetrics and Gynaecology, Mohtarma Benazir Bhutto Shaheed Medical College, Mirpur Khas 10250, Sindh, Pakistan
Marium Nausherwan, Department of Obstetrics and Gynaecology, Dartford and Gravesham NHS Trust, Dartford DA2 8DA, Kent, United Kingdom
Yamina Ishtiaq, Department of Obstetrics and Gynaecology, Shifa International Hospital, Islamabad 44000, Pakistan
Muhammad Dawood Hazoor, Department of Internal Medicine, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek 750065, Kyrgyzstan
Author contributions: Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, Ishtiaq Y, and Hazoor MD designed the research study; Jamil A, Sughra G, Abbasi GD, Adane S, Punshi M, Muhammad MG, Nausherwan M, and Ishtiaq Y performed the research; Hazoor MD contributed new analytic tools; Jamil A, Abbasi GD, and Hazoor MD analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: The approval by the Institutional Review Board waiver is granted due to its retrospective design involving de-identified medical records.
Informed consent statement: Informed consent was waived due to the retrospective nature of the study, which involved analysis of de-identified existing medical records.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: This manuscript is original, has not been published, and is not under consideration elsewhere.
Corresponding author: Muhammad Dawood Hazoor, MD, Department of Internal Medicine, International University of Kyrgyzstan, ISM IUK Eastern Campus, 6 Seven April Street, Bish
Received: November 3, 2025
Revised: November 17, 2025
Accepted: February 24, 2026
Published online: March 24, 2026
Processing time: 142 Days and 11.6 Hours
Revised: November 17, 2025
Accepted: February 24, 2026
Published online: March 24, 2026
Processing time: 142 Days and 11.6 Hours
Core Tip
Core Tip: This multicenter retrospective study of 234 women with atypical hyperplasia or early-stage endometrial cancer demonstrates fertility-sparing management’s efficacy, with 79.9% complete response, 25.1% recurrence, and 50.4% live birth rate. Innovatively, biomarkers (Ki-67 > 20%, human epididymis protein 4 > 50 pmol/L) independently predict recu